CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing immunity. Blocking this pathway restores immune function and improves survival ...

Vascularization plays a pivotal role, as inadequate blood supply can severely hinder healing. CD47, a protein present on nearly all human cells, has been linked to tissue regeneration and blood ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

ImmuneOnco allocated a chunk of the money for the development and planned launch of IMM2520, a CD47×PD-L1 bispecific that it named as a key product. The biotech set aside a further 10% of its IPO ...

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloid leukaemia (AML).